@article{PCM5018,
author = {Pasquale Pisapia and Francesco Pepe and Antonino Iaccarino and Giancarlo Troncone and Umberto Malapelle},
title = {Pathology in non-small cell lung cancer: evolving scenario},
journal = {Precision Cancer Medicine},
volume = {2},
number = {0},
year = {2019},
keywords = {},
abstract = {In 70–80% of advanced non small cell lung cancer (NSCLC) patients the only available material for both morphological diagnosis and molecular biomarkers assessment for the better treatment choice is represented by small tissue samples (small biopsies or cytological specimens). In order to avoid inadequate results due to the low amount of nucleic acids input and the difficulty to obtain tissue re-biopsies, the so called “liquid biopsy” could play a relevant role in this setting of patients. Tumoral DNA can be extracted from different body fluids [urine, saliva/sputum, cerebrospinal fluid (CSF), pleural effusion (PE)] of the patient or from supernatant sample of cytological preparations. In this review we analyzed the different the different “liquid biopsies” approaches.},
issn = {2617-2216}, url = {https://pcm.amegroups.org/article/view/5018}
}